FIELD: biotechnology.
SUBSTANCE: options of an anti-SIRPα antibody are proposed that are suitable for use in the anticancer therapy. The invention also relates to the use of anti-SIRPα antibodies in the treatment of solid tumors and hematological malignant neoplasms in a human, optionally in a combination with other anticancer therapeutic agents.
EFFECT: proposed anti-SIRPα antibodies demonstrate high affinity to SIRPα1 and SIRPαBIT and at the same time do not bind with SIRPγ, which provides advantages in using antibodies in the anticancer therapy.
15 cl, 4 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF THE USE THEREOF | 2015 |
|
RU2766094C2 |
| BISPECIFIC ANTIBODY | 2020 |
|
RU2814713C2 |
| ANTIBODIES DIRECTED AGAINST Fc-RECEPTOR-LIKE PROTEIN 5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2774158C2 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE THEREOF | 2018 |
|
RU2820628C2 |
| ANTI-PD-1 ANTIBODY | 2015 |
|
RU2722212C2 |
| BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF | 2020 |
|
RU2831836C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
